Skip to main content
OpenTrials
Completed

NCT Number: NCT04768400

MEP and Neuromuscular Blocker

It is important to predict the influence of the neuromuscular blocking agents on the motor evoked potential. Investigator will investigate the dose-response relationship between the degree of the neuromuscular blockade and the motor evoked potential in patients undergoing brain tumor surgery using the population approach. Investigator will investigate the influence of the other factors such as the impedence, reactance, muscel amount, and age on the motor evoked potential.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Brain Tumor Brain Diseases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

GangnamSeverance Hospital

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 19 years old or older, with American Society of Anesthesiologists Physical Status 1-3, and scheduled for elective brain tumor surgery under the monitoring of the motor evoked potential

Exclusion criteria

  • Central or peripheral neuromuscular disease
  • Sensory or motor nerve disorder
  • Allergy to propofol, remifentanil, and rocuronium
  • Patients with pacemaker

Treatment and study plan

Arm I (MEP)

Drug

Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.

Primary outcomes

  1. Amplitude of the motor evoked potential

    Time frame: At intraoperative 0 hr from the start of the anesthetic induction

    Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the start of the anesthetic induction.

Secondary outcomes

  1. Amplitude of the motor evoked potential

    Time frame: At intraoperative 0 h from the opening of the dura

    Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the opening of the dura.

Sponsors and collaborators

Lead sponsor

Gangnam Severance Hospital

Other

Registry information

Official study title

Quantitative Analysis Between Neuromuscular Blocking Agent and Motor Evoked Potential and Analysis of Risk Factors for the Coefficient of Variance of Motor Evoked Potential in Patients Undergoing Brain Tumor Removal Surgery: Population Approach

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Feb 24, 2021
Registry last updated
Jun 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.